Bridgewater Associates LP Invests $2.47 Million in Heska Co. (NASDAQ:HSKA)

Bridgewater Associates LP acquired a new position in shares of Heska Co. (NASDAQ:HSKA) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,737 shares of the medical research company’s stock, valued at approximately $2,467,000. Bridgewater Associates LP owned about 0.10% of Heska at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of HSKA. Altshuler Shaham Ltd acquired a new stake in Heska during the first quarter worth approximately $38,000. Benjamin F. Edwards & Company Inc. bought a new position in Heska in the first quarter valued at approximately $50,000. Point72 Hong Kong Ltd increased its stake in Heska by 858.0% in the first quarter. Point72 Hong Kong Ltd now owns 479 shares of the medical research company’s stock valued at $81,000 after acquiring an additional 429 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in Heska by 30.0% in the second quarter. Nisa Investment Advisors LLC now owns 520 shares of the medical research company’s stock valued at $119,000 after buying an additional 120 shares in the last quarter. Finally, Sageworth Trust Co acquired a new stake in Heska in the first quarter valued at approximately $92,000. Institutional investors and hedge funds own 94.92% of the company’s stock.

Several equities analysts recently issued reports on the stock. Alliance Global Partners restated a “buy” rating and issued a $310.00 target price (up previously from $240.00) on shares of Heska in a report on Wednesday, August 4th. Guggenheim raised shares of Heska from a “neutral” rating to a “buy” rating and set a $280.00 price objective for the company in a research report on Monday, July 12th. Piper Sandler upped their price objective on shares of Heska from $240.00 to $305.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 4th. Finally, Zacks Investment Research cut shares of Heska from a “buy” rating to a “hold” rating in a research note on Wednesday, October 6th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $268.00.

HSKA stock opened at $252.77 on Thursday. Heska Co. has a one year low of $103.00 and a one year high of $275.94. The company’s fifty day moving average price is $261.05 and its 200-day moving average price is $226.28. The company has a debt-to-equity ratio of 0.19, a quick ratio of 6.98 and a current ratio of 7.98. The company has a market capitalization of $2.69 billion, a PE ratio of -1,330.37 and a beta of 1.72.

Heska (NASDAQ:HSKA) last posted its quarterly earnings data on Tuesday, August 3rd. The medical research company reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.13. The business had revenue of $64.93 million for the quarter, compared to analysts’ expectations of $56.82 million. Heska had a negative net margin of 0.59% and a positive return on equity of 1.42%. The company’s revenue for the quarter was up 42.0% compared to the same quarter last year. On average, research analysts predict that Heska Co. will post 0.52 EPS for the current fiscal year.

In other news, CFO Catherine Grassman sold 5,000 shares of the stock in a transaction that occurred on Friday, August 6th. The stock was sold at an average price of $260.24, for a total transaction of $1,301,200.00. Following the transaction, the chief financial officer now owns 8,986 shares in the company, valued at approximately $2,338,516.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Sharon J. Larson sold 2,000 shares of the firm’s stock in a transaction on Tuesday, August 17th. The shares were sold at an average price of $266.83, for a total value of $533,660.00. Following the completion of the transaction, the director now owns 9,501 shares in the company, valued at approximately $2,535,151.83. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,000 shares of company stock valued at $2,105,190. Insiders own 8.60% of the company’s stock.

About Heska

Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through the North America and International segments. The North America segment includes the United States, Canada, and Mexico. The International segment involves Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland.

Recommended Story: How do candlesticks reflect price movement?

Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Co. (NASDAQ:HSKA).

Institutional Ownership by Quarter for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.